Literature DB >> 9067262

A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase.

N Makridakis1, R K Ross, M C Pike, L Chang, F Z Stanczyk, L N Kolonel, C Y Shi, M C Yu, B E Henderson, J K Reichardt.   

Abstract

Prostate cancer is the most common serious cancer diagnosed in men in the United States. This disease is also characterized by a striking racial/ethnic variation in incidence: highest in African-Americans, intermediate in Caucasians, slightly lower in Latinos, and lowest in Asians. Ample biochemical and epidemiological evidence suggests a role for androgens, particularly testosterone and dihydrotestosterone, in prostate cancer etiology. We have analyzed a candidate gene for prostate cancer, SRD5A2, encoding prostatic steroid 5alpha-reductase type II, which converts testosterone into the more bioactive dihydrotestosterone, for mutations. We report here one amino acid substitution, V89L, which replaces valine at codon 89 with leucine. This substitution is a "germline" (constitutional) DNA polymorphism, and it is common, panethnic, and reduces in vivo steroid 5alpha-reductase activity. This substitution is particularly common among Asians and may explain the low risk for prostate cancer in this population.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9067262

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

Review 1.  Racial differences in the androgen/androgen receptor pathway in prostate cancer.

Authors:  C A Pettaway
Journal:  J Natl Med Assoc       Date:  1999-12       Impact factor: 1.798

2.  Polymorphic changes in the KAL1 gene: not all of them should be classified as polymorphisms.

Authors:  D Söderlund; F Vilchis; J P Méndez
Journal:  J Endocrinol Invest       Date:  2004-09       Impact factor: 4.256

3.  Molecular Basis of Steroid Action in the Prostate.

Authors:  Yuan-Shan Zhu
Journal:  Cellscience       Date:  2005-04-28

4.  Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set.

Authors:  Jonathan Beesley; Susan J Jordan; Amanda B Spurdle; Honglin Song; Susan J Ramus; Suzanne Kruger Kjaer; Estrid Hogdall; Richard A DiCioccio; Valerie McGuire; Alice S Whittemore; Simon A Gayther; Paul D P Pharoah; Penelope M Webb; Georgia Chenevix-Trench
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-12       Impact factor: 4.254

Review 5.  Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview.

Authors:  S Salvi; V Conteduca; G Gurioli; D Calistri; V Casadio; U De Giorgi
Journal:  Mol Diagn Ther       Date:  2016-02       Impact factor: 4.074

6.  Molecular mechanisms involving prostate cancer racial disparity.

Authors:  David Hatcher; Garrett Daniels; Iman Osman; Peng Lee
Journal:  Am J Transl Res       Date:  2009-04-20       Impact factor: 4.060

7.  SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.

Authors:  Christine Neslund-Dudas; Cathryn H Bock; Kristin Monaghan; Nora L Nock; James J Yang; Andrew Rundle; Deliang Tang; Benjamin A Rybicki
Journal:  Prostate       Date:  2007-11-01       Impact factor: 4.104

8.  Metabolic syndrome in sub-Saharan Africa: "smaller twin" of a region's prostatic diseases?

Authors:  Chukwunonso E C C Ejike; Lawrence U S Ezeanyika
Journal:  Int Urol Nephrol       Date:  2008-02-21       Impact factor: 2.370

9.  Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study.

Authors:  Aruna V Sarma; Rodney L Dunn; Leslie A Lange; Anna Ray; Yunfei Wang; Ethan M Lange; Kathleen A Cooney
Journal:  Prostate       Date:  2008-02-15       Impact factor: 4.104

Review 10.  [Role of androgen receptors in hormone-refractory prostate cancer: molecular basics and experimental therapy approaches].

Authors:  L Rinnab; A Hessenauer; S V Schütz; E Schmid; R Küfer; F Finter; R E Hautmann; K D Spindler; M V Cronauer
Journal:  Urologe A       Date:  2008-03       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.